IPO: Codiak Biosciences Targets Exosomes

IPO: Codiak Biosciences Targets Exosomes

Codiak Biosciences is developing exosome-based therapeutics to treat diseases. Exosomes are naturally-occurring extracellular vesicles that carry proteins, genetic material, and other substances in and out of cells. Exosomes are like tiny bubbles that were originally believed to be a cellular waste product. Instead, exosomes can also be engineered for selective targeting of particular cells (ie. … Read more

Categories IPO

IPO: Cell Squeeze Technology Makes Debut With SQZ Biotechnologies Co

IPO: Cell Squeeze Technology Makes Debut With SQZ Biotechnologies Co

SQZ Biotechnologies Company filed last week with the U.S. Securities & Exchange Commission (SEC) to raise up to $75 million in an initial public offering (IPO). The company is developing cell therapies for cancer, infectious diseases, and other serious conditions. Its most advanced platform, SQZ Antigen Presenting Cells (SQZ APC), is currently in a Phase 1 trial … Read more

Categories IPO

IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare

IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare

U.S.-based cancer testing startup Grail Inc has filed for a U.S. initial public offering (IPO) to complete the commercialization of its population-scale multi-cancer early detection testing capability based on a technology called liquid biopsy. Grail was spun out of gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures … Read more

Categories IPO

IPO: Inhibrx’s Protein Engineering Targets Oncology and Orphans

IPO: Inhibrx’s Protein Engineering Targets Oncology and Orphans

Inhibrx, Inc is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx uses diverse methods of protein engineering to address the specific requirements of target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. The company has … Read more

Categories IPO

IPO: Harmony Biosciences Targets Narcolepsy

IPO: Harmony Biosciences Targets Narcolepsy

Harmony Biosciences is a private pharmaceutical company based in Plymouth Meeting, PA. Established in October 2017, the company’s vision is to develop and provide new medications to help people who are living with rare, neurological diseases. In October 2017, the company acquired exclusive U.S. rights to develop, register and market the drug pitolisant (WAKIX) from … Read more

Categories IPO

IPO: Biotech SPAC Panacea Acquisition Corp

IPO: Biotech SPAC Panacea Acquisition Corp

Panacea Acquisition is a special type of holding company designed to acquire operating companies in the biotechnology space. As a special purpose holding company (SPAC), the company has no operations other than a plan to go public with the intention of acquiring or merging with a company using the proceeds of its initial public offering … Read more

Categories IPO

IPO: Freeline Therapeutics Plans To Capitalize On Liver-directed Gene Therapies

IPO: Freeline Therapeutics Plans To Capitalize On Liver-directed Gene Therapies

Freeline Therapeutics is a UK-based biotechnology company that develops liver-directed gene therapies for bleeding disorders and other diseases. Its therapies are based on a next-generation proprietary AAV vector platform, specifically a gene therapy to treat haemophilia B. The company plans to raise $125 million by offering 7.4 million ADSs at a price range of $16 … Read more

Categories IPO

IPO: Curevac’s mRNA Play For Cures

IPO: Curevac’s mRNA Play For Cures

It all began with an unexpected discovery. CureVac’s founder, Dr. Ingmar Hoerr (a doctoral student at the time), discovered that when it was administered directly into tissue, the historically unstable biomolecule mRNA could be used as a therapeutic vaccine or agent after optimization—no complicated reformulations or molecular packaging needed. With a single discovery, CureVac opened … Read more

Categories IPO